H.C. Wainwright lowered the firm’s price target on BioCardia to $4 from $9 and keeps a Buy rating on the shares after the company disclosed interim efficacy results from the Phase 3 CardiAMP HF autologous cell therapy trial in patients with failure of reduced ejection fraction. The firm removed heart failure from its projections pending further visibility on a path forward.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BCDA:
- BioCardia provided update on its CardiAMP cell therapy programs
- BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
- BioCardia reports interim efficacy results in Phase 3 CardiAMP Cell Therapy
- BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
- BioCardia reports Q2 EPS (17c), consensus (16c)